Squamous Cell Carcinoma of the Head and Neck | Unmet Need | US/EU | 2021
For the past decade, Erbitux-based regimens have been the mainstay of treatment for recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck (SCCHN), but the launches of Merck & Co.’s Keytruda and Bristol Myers Squibb’s Opdivo are transforming the SCCHN treatment algorithm. However, despite the label expansions of these immune checkpoint inhibitors to include recurrent or metastatic non-nasopharyngeal SCCHN, more-efficacious first-line treatment options are needed to address the unmet needs pertaining to this subpopulation of SCCHN.
QUESTIONS ANSWERED
- What are the treatment drivers and goals in medical oncologists’ prescribing decisions for non-nasopharyngeal SCCHN?
- What are the hidden opportunities that developers could leverage?
- How do current therapies for non-nasopharyngeal SCCHN, such as Keytruda and Opdivo, perform on key clinical attributes for this patient population?
- What are the greatest unmet needs and most attractive opportunities in the treatment of non-nasopharyngeal SCCHN?
- What trade-offs are surveyed oncologists willing to make across key drug attributes and price when considering hypothetical target product profiles for non-nasopharyngeal SCCHN?
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in February 2021
Key companies: Merck & Co., Bristol Myers Squibb, Eli Lilly
Key drugs: Erbitux, Keytruda, Opdivo
